Functional Inclusion Bodies Produced in Bacteria as Naturally Occurring Nanopills for Advanced Cell Therapies

Authors

  • Esther Vázquez,

    1. Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain
    2. Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain
    3. CIBER en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Bellaterra, 08193 Barcelona, Spain
    Search for more papers by this author
  • José L. Corchero,

    1. Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain
    2. Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain
    3. CIBER en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Bellaterra, 08193 Barcelona, Spain
    Search for more papers by this author
  • Joan F. Burgueño,

    1. Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Bellaterra, 08193, Barcelona, Spain
    2. CIBER de Enfermedades Hepáticas y Digestivas (CIBER-EHD), CB06/04/0034, Bellaterra, 08193 Barcelona, Spain
    Search for more papers by this author
  • Joaquin Seras-Franzoso,

    1. Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain
    2. Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain
    3. CIBER en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Bellaterra, 08193 Barcelona, Spain
    Search for more papers by this author
  • Ana Kosoy,

    1. Janus Development SL, Parc Científic Barcelona, Torre R, Baldiri Reixach 4, 08028 Barcelona, Spain
    Search for more papers by this author
  • Ramon Bosser,

    1. Janus Development SL, Parc Científic Barcelona, Torre R, Baldiri Reixach 4, 08028 Barcelona, Spain
    Search for more papers by this author
  • Rosa Mendoza,

    1. Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain
    2. CIBER en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Bellaterra, 08193 Barcelona, Spain
    Search for more papers by this author
  • Joan Marc Martínez-Láinez,

    1. Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain
    2. Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain
    3. CIBER en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Bellaterra, 08193 Barcelona, Spain
    Search for more papers by this author
  • Ursula Rinas,

    1. Institute of Technical Chemistry-Life Science, Leibniz University of Hannover, 30167 Hannover, Germany
    2. Helmholtz Centre for Infection Research, Inhoffenstraße 7, 38124 Braunschweig, Germany
    Search for more papers by this author
  • Ester Fernández,

    1. Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Bellaterra, 08193, Barcelona, Spain
    2. CIBER de Enfermedades Hepáticas y Digestivas (CIBER-EHD), CB06/04/0034, Bellaterra, 08193 Barcelona, Spain
    Search for more papers by this author
  • Luis Ruiz-Avila,

    1. Janus Development SL, Parc Científic Barcelona, Torre R, Baldiri Reixach 4, 08028 Barcelona, Spain
    Search for more papers by this author
  • Elena García-Fruitós,

    Corresponding author
    1. Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain
    2. Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain
    3. CIBER en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Bellaterra, 08193 Barcelona, Spain
    • Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain.
    Search for more papers by this author
  • Antonio Villaverde

    Corresponding author
    1. Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain
    2. Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain
    3. CIBER en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Bellaterra, 08193 Barcelona, Spain
    • Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain.
    Search for more papers by this author

Abstract

original image

Inclusion bodies (50–500 nm in diameter) produced in recombinant bacteria can be engineered to contain functional proteins with therapeutic potential. Upon exposure, these protein particles are efficiently internalized by mammalian cells and promote recovery from diverse stresses. Being fully biocompatible, inclusion bodies are a novel platform, as tailored nanopills, for sustained drug release in advanced cell therapies.

Ancillary